Regulation 30 of the Securities and Exchange Board of India ( Listing Obligation and Disclosure Requirement ) Regulation, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Shukra Pharmaceuticals, at its meeting on November 29, 2025, approved the continuation of Mr. Jitendra Somchand Shah (DIN: 01609325) as Non-Executive Independent Director. Mr. Shah, who was originally appointed on July 10, 2024 and confirmed at the 31st AGM for a five-year term, turned 75 years old on September 22, 2025. Under SEBI's Regulation 17(1A), shareholders must approve such continuation via a Postal Ballot. The Board approved the draft Postal Ballot notice and appointed Mrs. Rupal Patel, Practicing Company Secretary, as the Scrutinizer for the Postal Ballot process. The filing confirms Mr. Shah is not debarred from holding directorship by any SEBI order.
This is a routine regulatory filing with no material impact on the stock. The continuation is subject to shareholder approval through Postal Ballot, which is a procedural requirement when an Independent Director crosses 75 years of age. No change in the company's business or financial outlook.